Results 161 to 170 of about 12,163 (174)

Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study

Thrombosis Research, 2020
Saskia Middeldorp, Frits I Mulder, Tzu-Fei Wang   +2 more
exaly  

Population pharmacokinetics of edoxaban and its main metabolite in a dedicated renal impairment study

Journal of Clinical Pharmacology, 2015
Siv Jonsson, Ulrika Simonsson, Mats Karlsson   +2 more
exaly  

Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial

Circulation, 2018
Jeffrey Weitz, Eugene Braunwald
exaly  

The impact of a three-factor prothrombin complex concentrate on the anticoagulatory effects of the factor Xa inhibitor edoxaban

Thrombosis Research, 2015
Minggao Shi
exaly  

Edoxaban for treatment of venous thromboembolism in patients with cancer

Thrombosis and Haemostasis, 2015
Nick van Es, Marcello di Nisio, Peter Verhamme   +2 more
exaly  

Edoxaban: Impact on routine and specific coagulation assays

Thrombosis and Haemostasis, 2016
François Mullier, Jonathan Douxfils, Christian Chatelain   +2 more
exaly  

Short-Term Safety and Plasma Concentrations of Edoxaban in Japanese Patients With Non-Valvular Atrial Fibrillation and Severe Renal Impairment

Circulation Journal, 2015
Masayuki Fukuzawa, Masahiro Yasaka
exaly  

Bioavailability and Safety of the Factor Xa Inhibitor Edoxaban and the Effects of Quinidine in Healthy Subjects

Clinical Pharmacology in Drug Development, 2013
exaly  

Factors related to inappropriate edoxaban use

Journal of Clinical Pharmacy and Therapeutics, 2019
Myung Koo Lee, Sandy Rhie
exaly  

Edoxaban drug–drug interactions with ketoconazole, erythromycin, and cyclosporine

British Journal of Clinical Pharmacology, 2016
exaly